RXST
$6.89
$-0.12 (-1.71%)-1.71%
ClosedLoading chart...
IndexN/A
Market Cap0.29B
Enterprise Value0.42B
Income$-0.01B
Sales$0.04B
EmployeesN/A
P/E-7.41
P/S3.19
P/B1.56
P/C-22.18
EV/EBITDA-10.82
EV/SalesN/A
EPS (ttm)-0.93
EarningsN/A
Gross Margin76.60%
Oper. Margin-35.84%
Profit Margin-28.96%
Volume0.48M
Shs Outstand0.04B
Change-1.71%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $139.93M | $89.08M | $49.01M | $22.59M | $14.68M | $2.24M |
| Cost of Revenue | $40.98M | $35.31M | $27.68M | $18.08M | $12.97M | $4.06M |
| Gross Profit | $98.94M | $53.77M | $21.33M | $4.52M | $1.71M | $-1.82M |
| Gross Margin | 70.71% | 60.36% | 43.52% | 19.99% | 11.62% | -81.17% |
| Operating Expenses | $135.80M | $103.85M | $84.65M | $57.30M | $37.11M | $44.25M |
| Operating Income | $-36.86M | $-50.09M | $-63.32M | $-52.79M | $-35.41M | $-46.07M |
| Operating Margin | -26.34% | -56.23% | -129.21% | -233.64% | -241.21% | -2055.78% |
| Net Income | $-27.45M | $-48.61M | $-66.76M | $-48.69M | $27.57M | $126.22M |
| Net Margin | -19.62% | -54.57% | -136.22% | -215.50% | 187.87% | 5632.31% |
| EPS (Basic) | $-0.71 | $-1.41 | $-2.41 | $-1.78 | $0.18 | $0.95 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $318.56M | $182.55M | $150.16M | $192.72M | $100.68M | $110.43M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $37.33M | $22.19M | $60.26M | $54.48M | $398.21M | $415.04M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $281.24M | $160.36M | $89.90M | $138.24M | $-297.53M | $-304.61M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $281.24M | $160.36M | $89.90M | $138.24M | $-297.53M | $-304.61M |
| Total Liabilities & Stockholders Equity | $318.56M | $182.55M | $150.16M | $192.72M | $100.68M | $110.43M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-27.45M | $-48.61M | $-66.76M | $-48.69M | $27.57M | $126.22M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-16.95M | $-41.59M | $-58.85M | $-44.71M | $-35.20M | $-40.62M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial OfficerGlobeNewswire Inc. RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXSTBenzinga SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSightGlobeNewswire Inc. מחר המועד האחרון לתביעה נגד RXST: רוזן, יועץ למשקיעים מוביל, מעודד משקיעים ב- .RxSight, Inc עם הפסדים של יותר מ-100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב של 22 בספטמבר בתביעה ייצוגית בניירות ערך - RXSTGlobeNewswire Inc. RXST DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages RxSight, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action – RXSTGlobeNewswire Inc. מחר המועד האחרון לתביעה נגד REPL: רוזן, יועץ למשקיעים מיומן, מעודד את משקיעי Replimune Group, Inc. שצברו הפסדים של יותר מ- 100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך שהוגשה ראשונה על ידי המשרד – REPLGlobeNewswire Inc. INVESTOR CLASS ACTION: RxSight, Inc. Investors are Reminded of the Ongoing Securities Fraud Lawsuit after Stock Plummeted 38% -- Contact BFA LawGlobeNewswire Inc. RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law FirmBenzinga
Show 12 more stories
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSightGlobeNewswire Inc. Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against RxSight, Inc. (RXST)GlobeNewswire Inc. RXSIGHT DEADLINEALERT: Bragar Eagel & Squire, P.C. Reminds RXST Investors that a Class Action Lawsuit Has Been Filed Against RxSight, Inc. and Encourages Investors to Contact the Firm Before September 22ndGlobeNewswire Inc. RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire Inc. RXST DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages RxSight, Inc. Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action – RXSTGlobeNewswire Inc. RxSight, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.GlobeNewswire Inc. RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitGlobeNewswire Inc. Class Action Filed Against RxSight, Inc. (RXST) Seeking Recovery for Investors – Contact The Gross Law FirmGlobeNewswire Inc. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against RxSight, Inc. (NASDAQ: RXST)GlobeNewswire Inc. RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXSTBenzinga RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law FirmBenzinga RXST DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages RxSight, Inc. Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action – RXSTGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Discover more
You may be interested in